Neurosov has developed an innovative molecule that slows the progression of Parkinson's disease. It is dedicated to research and development (R&D) using preclinical validation models, both in vitro and in vivo, of molecules with therapeutic potential for Parkinson's disease (and other neurological diseases); It also develops scientific studies and tests targeting Parkinson's and other neurological diseases, with a special focus on the development of new therapies for these diseases, as well as diagnostic tests (kits) or evaluation of pathological mechanisms associated to them; biological toxicity tests, of products targeting the human consumption market, for example agro-food, paper, biotechnology, etc.